Edwards Lifesciences Enhances Shareholder Value Post-Divestiture
Express News | Edwards Lifesciences Corp - Company Announces $1 Bln Share Repurchase
BD Completes Acquisition of Critical Care From Edwards Lifesciences
Express News | Edwards Lifesciences Completes Sale of Critical Care
Edwards Lifesciences Reports Positive TAVI Trial Results
First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
Peering Into Edwards Lifesciences's Recent Short Interest
Investors in Edwards Lifesciences (NYSE:EW) Have Unfortunately Lost 43% Over the Last Three Years
J.P. Morgan Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Announces Target Price $72
Balanced Outlook: Hold Rating on Edwards Lifesciences Amidst Market Uncertainties and Growth Potential
Bain & Company: Large-scale M&A transactions are mainly concentrated in the nengyuanhangye industry. M&A activities in the technology industry remain active.
Bain & Company releases its mid-year report on the global M&A market for 2024.
Could The Market Be Wrong About Edwards Lifesciences Corporation (NYSE:EW) Given Its Attractive Financial Prospects?
Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue?
Following a 7.7% Decline Over Last Year, Recent Gains May Please Edwards Lifesciences Corporation (NYSE:EW) Institutional Owners
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $83
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $85
Edwards Lifesciences: A Strong Buy on Market Expansion and Innovative Cardiovascular Solutions
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference
Oppenheimer's Top 32 Ideas for August-September